AI in clinical trials has transformed healthcare; however significant legal, ethical challenges remain, ET HealthWorld
London: The integration of artificial intelligence (AI) in clinical trials has transformed healthcare by enhancing data analysis, predicting outcomes, and expediting drug development. However, this innovation comes with significant legal and ethical challenges, as AI systems rely heavily on vast datasets from clinical trials, raising concerns about consent, data origin, and ethical standards, says GlobalData.
Transparency regarding data collection methods and anonymisation is critical, especially when data is sourced from third parties. While consent forms help outline data usage during trials, ambiguity persists around reusing such data for AI purposes after trials conclude.
Medical analysts at the 2024 Medtech Conference session, ‘Unlocking Health Data: Navigating the Legal Landmines for Innovation’, highlighted the pressing need for actionable solutions. They emphasised that data ownership remains a grey area, often causing disputes between clinical trial sponsors, healthcare providers, and AI developers.
Elia Garcia, Medical Analyst, GlobalData, commented, “Clear ownership frameworks would not only promote transparency but also reduce conflicts over data-sharing practices. Analysts also noted the importance of simplifying complex regulatory language to help healthcare providers understand and align with AI development goals.”
Cybersecurity is a significant concern, as health data is highly susceptible to breaches, potentially resulting in identity theft, fraud, and other serious risks. Ethical issues further complicate the landscape; the misuse of health data can provoke negative public reactions and diminish trust in healthcare providers and AI technologies.
Garcia concluded, “Navigating the legal and ethical challenges in AI-driven clinical trials requires collaborative efforts between policymakers, healthcare providers, and AI developers. By adopting clear data ownership frameworks, enhancing communication, and educating the public, the industry can address concerns while continuing to innovate. These measures, coupled with risk-based regulations, pave the way for a secure, ethical, and progressive AI-driven healthcare landscape.”>
